{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:00:35Z","timestamp":1783472435793,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.vaccine.2021.12.047","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T06:05:30Z","timestamp":1641362730000},"page":"742-751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases"],"prefix":"10.1016","volume":"40","author":[{"given":"Shaleesa","family":"Ledlie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunshen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Khromava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.12.047_b0005","first-page":"77","article-title":"The yellow fever vaccine: a history","volume":"83","author":"Frierson","year":"2010","journal-title":"Yale J Biol Med."},{"key":"10.1016\/j.vaccine.2021.12.047_b0010","first-page":"1","article-title":"Yellow fever vaccine: recommendations of the advisory committee on immunization practices (ACIP)","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"17","key":"10.1016\/j.vaccine.2021.12.047_b0015","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15585\/mmwr.mm6617e2","article-title":"Addressing a yellow fever vaccine shortage \u2014 United States, 2016\u20132017","volume":"66","author":"Gershman","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2021.12.047_b0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11908-017-0566-9","article-title":"Live attenuated yellow fever 17D vaccine: a legacy vaccine still controlling outbreaks in modern day","volume":"19","author":"Collins","year":"2017","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.vaccine.2021.12.047_b0025","unstructured":"World Health Organization. World \u2013 Yellow fever vaccination booster. https:\/\/www.who.int\/ith\/updates\/20140605\/en\/. Published 2014. Accessed May 2021."},{"key":"10.1016\/j.vaccine.2021.12.047_b0030","unstructured":"World Health Organization. WHO position paper on vaccines and vaccination against yellow fever. https:\/\/www.who.int\/immunization\/newsroom\/news_WHO_position_paper_yellow_fever\/en\/. Accessed May, 2021."},{"issue":"1","key":"10.1016\/j.vaccine.2021.12.047_b0035","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tay108","article-title":"Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers","volume":"25","author":"Lindsey","year":"2018","journal-title":"J Travel Med"},{"issue":"8","key":"10.1016\/j.vaccine.2021.12.047_b0040","doi-asserted-by":"crossref","first-page":"taab126","DOI":"10.1093\/jtm\/taab126","article-title":"Long-term immunity after a single yellow fever vaccination in travelers vaccinated at 60 years or older: A 10-year follow-up study","volume":"28","author":"Rosenstein","year":"2021","journal-title":"J Travel Med"},{"issue":"5","key":"10.1016\/j.vaccine.2021.12.047_b0045","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.4161\/hv.28117","article-title":"The yellow fever 17D virus as a platform for new live attenuated vaccines","volume":"10","author":"Bonaldo","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"48","key":"10.1016\/j.vaccine.2021.12.047_b0050","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.12.047_b0055","unstructured":"Centers for Disease Control and Prevention (CDC). Contraindications for Administering Yellow Fever Vaccine. https:\/\/www.cdc.gov\/travel-training\/local\/HistoryEpidemiologyandVaccination\/contraindications-administering-yellow-fever-vaccine.pdf. Accessed April 2021."},{"issue":"6","key":"10.1016\/j.vaccine.2021.12.047_b0060","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/jtm.12070","article-title":"Safety of the yellow fever vaccine: a retrospective study","volume":"20","author":"Nordin","year":"2013","journal-title":"J Travel Med"},{"issue":"25","key":"10.1016\/j.vaccine.2021.12.047_b0065","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events","volume":"23","author":"Khromava","year":"2005","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2021.12.047_b0070","doi-asserted-by":"crossref","first-page":"taw045","DOI":"10.1093\/jtm\/taw045","article-title":"Adverse event reports following yellow fever vaccination, 2007\u201313","volume":"23","author":"Lindsey","year":"2016","journal-title":"J Travel Med"},{"issue":"33","key":"10.1016\/j.vaccine.2021.12.047_b0075","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1016\/j.vaccine.2012.04.067","article-title":"Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"30","author":"Gershman","year":"2012","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.vaccine.2021.12.047_b0080","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1016\/j.vaccine.2014.08.051","article-title":"Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)","volume":"32","author":"Seligman","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.12.047_b0085","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2021.12.047_b0090","unstructured":"Optum EHR. Ignite insights with Optum EHR data. 2020. https:\/\/www.optum.com\/content\/dam\/optum3\/optum\/en\/resources\/sell-sheet\/ehr-data-sell-sheet.pdf. Accessed April 2021."},{"key":"10.1016\/j.vaccine.2021.12.047_b0095","unstructured":"Optum. Clinical\/EHR Data. 2020. https:\/\/www.optum.com\/business\/solutions\/government\/federal\/data-analytics-federal\/clinical-data.html. Accessed April 2020."},{"key":"10.1016\/j.vaccine.2021.12.047_b0100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s13104-015-1217-6","article-title":"Benefits of applying a proxy eligibility period when using electronic health records for outcomes research: a simulation study","volume":"8","author":"Yu","year":"2015","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.vaccine.2021.12.047_b0105","unstructured":"Optum. Clinformatics Data Mart. 2014. https:\/\/www.optum.com\/content\/dam\/optum\/resources\/productSheets\/Clinformatics-Data-Mart.pdf. Accessed April 2021."},{"key":"10.1016\/j.vaccine.2021.12.047_b0110","article-title":"IBM MarketScan Research Databases for life science researchers. IBM Watson","author":"Hansen","year":"2017","journal-title":"Health."},{"issue":"10","key":"10.1016\/j.vaccine.2021.12.047_b0115","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.vaccine.2006.11.027","article-title":"Neurologic disease associated with 17D\u2013204 yellow fever vaccination: a report of 15 cases","volume":"25","author":"McMahon","year":"2007","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2021.12.047_b0120","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.4269\/ajtmh.2009.09-0295","article-title":"Short report: Incidence of yellow fever vaccine-associated neurotropic disease","volume":"81","author":"Guimard","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2021.12.047_b0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion","volume":"16","author":"Brown","year":"2001","journal-title":"Stat Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2021.12.047_b0130","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3390\/tropicalmed5030125","article-title":"Ensuring the safety of yellow fever vaccination in travelers\u2014the experience at a large U.S. academic medical center in Colorado","volume":"5","author":"Bandali","year":"2020","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.vaccine.2021.12.047_b0135","unstructured":"Centers for Disease control and Prevention (CDC). Yellow Fever Vaccine Course. 2019. https:\/\/wwwnc.cdc.gov\/travel\/page\/yellow-fever-vaccine-course. Accessed June, 2021."},{"key":"10.1016\/j.vaccine.2021.12.047_b0140","unstructured":"Centers for Disease control and Prevention (CDC). Yellow Fever Vaccine Information for Healthcare Providers. 2020. https:\/\/www.cdc.gov\/yellowfever\/healthcareproviders\/vaccine-info.html. Accessed August 2021."},{"key":"10.1016\/j.vaccine.2021.12.047_b0145","unstructured":"Sanofi Pasteur. STA00011 Expanded Access Program. 2017. Inclusion\/Exclusion Criteria Protocol Amendment 3 Web site. https:\/\/campushealth.unc.edu\/sites\/campushealth.unc.edu\/files\/documents\/Stamaril%20Inclusion_Exclusion%20checklist.pdf. Accessed August 2021."},{"issue":"43","key":"10.1016\/j.vaccine.2021.12.047_b0150","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1016\/j.vaccine.2009.07.082","article-title":"Viscerotropic disease following yellow fever vaccination in Peru","volume":"27","author":"Whittembury","year":"2009","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2021.12.047_b0155","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2105\/AJPH.85.12.1706","article-title":"The reporting sensitivities of two passive surveillance systems for vaccine adverse events","volume":"85","author":"Rosenthal","year":"1995","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2021.12.047_b0160","series-title":"Vaccines","author":"Plotkin","year":"2013"},{"issue":"5","key":"10.1016\/j.vaccine.2021.12.047_b0165","doi-asserted-by":"crossref","first-page":"954","DOI":"10.4269\/ajtmh.12-0463","article-title":"Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009\u20132011","volume":"88","author":"Jentes","year":"2013","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"10.1016\/j.vaccine.2021.12.047_b0170","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa172","article-title":"A clinician's perspective on yellow fever vaccine-associated neurotropic disease","volume":"27","author":"Lecomte","year":"2020","journal-title":"J Travel Med"},{"issue":"9438","key":"10.1016\/j.vaccine.2021.12.047_b0175","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(04)17017-7","article-title":"History of thymoma and yellow fever vaccination","volume":"364","author":"Barwick Eidex","year":"2004","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21016558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21016558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:06:14Z","timestamp":1759403174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21016558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0264410X21016558"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.047","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}